KC-3617

Ba/F3-TROP2 Cell Line

×
34552
Home » Ba/F3-TROP2 Cell Line

Background of Ba/F3-TROP2 Cell Line

TROP2 (Trophoblast cell-surface antigen 2) , encoded by the TACSTD2 gene on chromosome 1p32, is a 323-amino-acid transmembrane glycoprotein that functions as a calcium signal transducer. It is also known as EGP-1, GA733-1, and M1S1. In normal tissues, TROP2 expression is largely restricted to epithelial lineages, with the highest tumor-to-normal expression differences observed in cervical, head and neck, and bladder cancers. TROP2 is broadly overexpressed in numerous epithelial malignancies, including triple-negative breast cancer (TNBC), non-small cell lung cancer, and urothelial carcinoma, where it promotes tumor growth, invasion, and metastasis through PI3K/AKT, JAK/STAT, and MAPK pathways. Sacituzumab govitecan (SG) , the first TROP2-directed antibody-drug conjugate (ADC), received FDA approval in 2020 for metastatic TNBC, paving the way for next-generation agents such as datopotamab deruxtecan (Dato-DXd) and sacituzumab tirumotecan.

Specifications

Catalog NumberKC-3617
Cell Line NameBa/F3-TROP2 Cell Line
NCBI/UniProt Accession NumberNM_002353.3
Clone Number2#
Host Cell LineBa/F3 Cell Line
DescriptionStable Ba/F3 cell line expressing exogenous human TROP2 gene
QuantityOne vial of frozen cells (≥2×10⁶ cells/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640+20%FBS+10%DMSO
Propagation MediumRPMI1640+10%FBS+1000µg/mL G418+8 ng/mL mouse IL-3
Selection MarkerG418
MorphologyLymphoblast-like
SubcultureSplit at a ratio of 1:10 every 2–3 days
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeEstimated 14–22 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

The Ba/F3-TROP2 cell line was generated by lentiviral transduction of Ba/F3 cells to stably express human TROP2.

Characterization

Figure 1: Characterization of human TROP2 overexpression in the Ba/F3-TROP2 stable clone using FACS.

Figure 2: Characterization of human TROP2 overexpression in the Ba/F3-TROP2 stable clone using PCR sequencing.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, then carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask at 37°C in a humidified 5% CO₂ incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium.
  9. Subculture the cells at a ratio of 1:10 every 2–3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% RPMI1640, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to liquid nitrogen for long-term storage the following day.

References

1. Liu X, Ma L, Li J, Sun L, Yang Y, Liu T, Xing D, Yan S, Zhang M. Trop2-targeted therapies in solid tumors: advances and future directions. Theranostics. 2024 Jun 11;14(9):3674-3692. doi: 10.7150/thno.98178. PMID: 38948057; PMCID: PMC11209721.
2. Hu Y, Zhu Y, Qi D, Tang C, Zhang W. Trop2-targeted therapy in breast cancer. Biomark Res. 2024 Aug 13;12(1):82. doi: 10.1186/s40364-024-00633-6. PMID: 39135109; PMCID: PMC11321197.
3. Nelson BE, Meric-Bernstam F. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors. Annu Rev Med. 2024 Jan 29;75:31-48. doi: 10.1146/annurev-med-071322-065903. Epub 2023 Sep 27. PMID: 37758237.

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.